TY - JOUR
T1 - Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting
T2 - The Mayo Clinic Experience
AU - Singhal, Sachi
AU - Saadeh, Salwa S.
AU - Durani, Urshila
AU - Kansagra, Ankit
AU - Alkhateeb, Hassan B.
AU - Shah, Mithun V.
AU - Mangaonkar, Abhishek
AU - Kenderian, Saad
AU - Hashmi, Shahrukh
AU - Patnaik, Mrinal V.
AU - Litzow, Mark R.
AU - Hogan, William J.
N1 - Funding Information:
S.K. reports patents and royalties from Novartis, Humanigen, Mettaforge, and MustangBio; research funding from Novartis, Kite/Gilead, Juno/BMS, Humanigen, Lentigen, Morphosys, Tolero, and Sunesis; and advisory board membership for Kite/Gilead, Juno/BMS, Novartis, and Humanigen. A.K. reports advisory board membership for Abbvie, BMS/Celgene, Cota Health, GSK, and Janssen; and employment with Janssen.
Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2023/3
Y1 - 2023/3
N2 - Hematopoietic stem cell transplantations (HSCT) are intensive and potentially curative modalities available for a variety of hematological diseases. Although alloHSCTs are typically performed in an inpatient setting, there has been increasing interest in moving them to the outpatient setting. AlloHSCTs are associated with a median length of hospital stay of 30 days. AlloHSCTs in the inpatient setting may increase patient exposure to nosocomial infections, drug-resistant organisms, rapid deconditioning with time spent in hospital beds, and loss of muscle mass. In this study, we aim to share outcomes of 856 consecutive alloHSCTs done in our institute over the past 2 decades. This is a single-center retrospective chart review encompassing 856 patients who underwent outpatient alloHSCTs between 2000 and 2017. Reduced-intensity conditioning, stem cell infusion, and much of the immediate follow-up in the early alloHSCT period was performed on an outpatient basis with daily evaluation, laboratory assessment, and intervention as needed. Rate of non-routine hospital admission was our primary outcome of interest. We also looked at various secondary outcomes, including causes of admission, median length of stay, and in-hospital mortality rate. Data analysis was performed using STATA statistical software Version 15. Descriptive statistics were used to summarize baseline demographic data and outcomes. Logistic regression modeling was used to identify predictors of hospital admission. We observed that about one third of our cohort never required admission to the hospital throughout the first 100 days after HSCT. Among those admitted, 6.6% experienced a direct admission to the intensive care unit, and the overall in hospital mortality was low at 5%. Furthermore, the median length of stay was noted to be decreased at 6 days compared to a median reported 30 days in existing literature. Overall, we observed favorable safety profile and outcomes with outpatient management of HSCTs.
AB - Hematopoietic stem cell transplantations (HSCT) are intensive and potentially curative modalities available for a variety of hematological diseases. Although alloHSCTs are typically performed in an inpatient setting, there has been increasing interest in moving them to the outpatient setting. AlloHSCTs are associated with a median length of hospital stay of 30 days. AlloHSCTs in the inpatient setting may increase patient exposure to nosocomial infections, drug-resistant organisms, rapid deconditioning with time spent in hospital beds, and loss of muscle mass. In this study, we aim to share outcomes of 856 consecutive alloHSCTs done in our institute over the past 2 decades. This is a single-center retrospective chart review encompassing 856 patients who underwent outpatient alloHSCTs between 2000 and 2017. Reduced-intensity conditioning, stem cell infusion, and much of the immediate follow-up in the early alloHSCT period was performed on an outpatient basis with daily evaluation, laboratory assessment, and intervention as needed. Rate of non-routine hospital admission was our primary outcome of interest. We also looked at various secondary outcomes, including causes of admission, median length of stay, and in-hospital mortality rate. Data analysis was performed using STATA statistical software Version 15. Descriptive statistics were used to summarize baseline demographic data and outcomes. Logistic regression modeling was used to identify predictors of hospital admission. We observed that about one third of our cohort never required admission to the hospital throughout the first 100 days after HSCT. Among those admitted, 6.6% experienced a direct admission to the intensive care unit, and the overall in hospital mortality was low at 5%. Furthermore, the median length of stay was noted to be decreased at 6 days compared to a median reported 30 days in existing literature. Overall, we observed favorable safety profile and outcomes with outpatient management of HSCTs.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Bone marrow
KW - Outpatient transplant
UR - http://www.scopus.com/inward/record.url?scp=85147101306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147101306&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.12.016
DO - 10.1016/j.jtct.2022.12.016
M3 - Article
C2 - 36584940
AN - SCOPUS:85147101306
SN - 2666-6375
VL - 29
SP - 183.e1-183.e6
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 3
ER -